Cancer drug resistance in multiple myeloma

INTRODUCTION Multiple myeloma(MM)is the second most common hematologic malignancy after non-Hodgkin’s lymphoma.Intrinsic and acquired drug resistance of cancer cells to standard drugs is a major obstacle for a more successful survival outcome of MM patients treated on contemporary clinical protocols.The primary purpose of this special issue on“Drug Targets and Resistance Mechanisms in Multiple Myeloma”was to collect new and transformative information regarding new insights about the mechanisms of drug resistance in MM and the role of the tumor microenvironment in treatment failures.